Abstract
Objective: Overdoses remain a major public health challenge. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been proposed as a treatment for opioid use disorder (OUD) based on preclinical research. Early observational research suggests that GLP-1RAs are associated with reduced opioid overdoses but warrants replication in different patient populations.
Methods: This target trial emulation study used Veterans Health Administration (VA) data to include Veterans with a diagnosis of type 2 diabetes mellitus and OUD who initiated semaglutide and tirzepatide or a comparison diabetes medication (insulin, metformin, a sulfonylurea, a sodium-glucose transport 2 (SGLT2) inhibitor, or a dipeptidyl-peptidase 4 [DPP4] inhibitor) between January 1, 2020, and December 31, 2024. Each set of comparison groups was propensity score matched on relevant variables. Cox proportional hazards regression models were used to compare the time to all-cause overdose events in the 12 months after medication initiation.
Results: After propensity score matching, semaglutide and tirzepatide were associated with significantly lower risk of all-cause overdose compared to insulin (hazard ratio [HR]=0.32; 95% CI=0.14–0.71; P=.006; n=630) and SGLT2 inhibitors (HR=0.25; 95% CI=0.09–0.68; P=.006; n=432). Semaglutide and tirzepatide were not associated with significantly lower risks than metformin (HR=0.75; 95% CI=0.38–1.45; n=1,016), sulfonylureas (HR=0.82; 95% CI=0.33–1.96; n=710), or DPP4 inhibitors (HR=1.20; 95% CI=0.52–2.78; n=858).
Conclusion: Collectively, semaglutide and tirzepatide were associated with lower risk of all-cause overdose compared to insulin and SGLT2 inhibitors, but not metformin, sulfonylureas, or DPP4 inhibitors. These results suggest the possible role of GLP-1RAs in OUD but underscore the need for randomized controlled trials.
J Clin Psychiatry 2026;87(3):25m16212
Author affiliations are listed at the end of this article.
Members Only Content
This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.
References (18)
- Post LA, Ciccarone D, Unick GJ, et al. Decline in US drug overdose deaths by region, substance, and demographics. JAMA Netw Open. 2025;8(6):e2514997. PubMed CrossRef
- Dowell D, Brown S, Gyawali S, et al. Treatment for opioid use disorder: population estimates — United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;73(25):567–574. doi:10.15585/mmwr.mm7325a1. PubMed CrossRef
- Gordon AJ, Saxon AJ, Kertesz S, et al. Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug Alcohol Depend. 2023;248:109902. PubMed CrossRef
- Nosyk B, Min JE, Homayra F, et al. Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder. JAMA. 2024;332(21):1822–1831. PubMed CrossRef
- De Giorgi R, Ghenciulescu A, Dziwisz O, et al. An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders. Nat Ment Health. 2025;3(3):354–373. PubMed CrossRef
- Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis. Addiction. 2025;120(2):236–250. PubMed CrossRef
- Wang W, Volkow ND, Wang Q, et al. Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder. JAMA Netw Open. 2024;7(9):e2435247. PubMed CrossRef
- Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–161. PubMed CrossRef
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. R Stat Soc J Ser B Methodol. 1995;57(1):289–300. CrossRef
- VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274. PubMed CrossRef
- Cai M, Choi T, Xie Y, et al. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026;392:e086886. doi:10.1136/bmj-2025-086886 PubMedCrossRef
- Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15(1):4548. PubMed CrossRef
- Farokhnia M, Tazare J, Pince CL, et al. Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake. J Clin Investig. 2025;6(9):e188314. Published online March. doi:10.1172/JCI188314. PubMed CrossRef
- Chan A, Willard A, Mulloy S, et al. Metformin in nucleus accumbens core reduces cue-induced cocaine seeking in male and female rats. Addict Biol. 2022;27(3):e13165. doi:10.1111/adb.13165. PubMedCrossRef
- Listos J, Listos P, Baranowska-Bosiacka I, et al. Linagliptin, a selective dipeptidyl Peptidase-4 inhibitor, reduces physical and behavioral effects of morphine withdrawal. Molecules. 2022;27(8):2478. PubMed CrossRef
- Łupina M, Talarek S, Kotlińska J, et al. The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats. Neurochem Int. 2020;133:104616. PubMed CrossRef
- Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753–768. PubMed CrossRef
- Sharma AN, Pise A, Sharma JN, et al. Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats. Metab Brain Dis. 2015;30(3):719–730. PubMed CrossRef
